Navigation Links
Voices Against Brain Cancer Responds to Research Identifying Contributing Factor in Brain Tumors
Date:4/5/2013

Bohemia, NY (PRWEB) April 05, 2013

On April 5, 2013, Voices Against Brain Cancer (VABC) responds to an article posted by Bioscience Technology detailing how the blockage of molecular pathways in the brain could be a contributing factor in the development of brain tumors.

The Bioscience Technology article states that a coalition of researchers from various institutions have apparently identified pathways in the brain that feed the growth of brain tumors leading to medulloblastoma. Medulloblastoma, described as the most common form of brain cancer among children, might be a product of the interaction between tumor cells and neighboring tissue as a result of blockages, according to the article.

“A highly malignant tumor that originates in the cerebellum, medulloblastoma accounts for about 20 percent of all pediatric brain tumors and is ten times more common in children than in adults. While aggressive treatment with surgery, chemotherapy and radiation significantly improves patient survival, those treatments can have long-term developmental, behavioral and neurological side effects, particularly in the youngest patients, making the need for less damaging therapies essential.”

The article emphasizes placental growth factor (PIGF) as the most likely cause for the development of medulloblastoma. Researchers “were surprised to find” that PIGF is influenced by the surrounding tissue and not by tumor cells. Since medulloblastoma cells are credited with the release of an enabling protein, signals are produced that stimulate the needed conditions to feed tumor growth.

Michael Klipper, Chairman for Voices Against Brain Cancer, responds to the findings of the medulloblastoma research. “Few things can compare to the devastating thought that a child could be deprived of a full life and promising future. Understanding how brain cancer originates and develops is the top priority for researchers in the field. If current research is developing a way to identify how medulloblastoma tumors grow, it is reasonable to assume that treatment options will develop in its wake.”

VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.

VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.

For press inquiries, please contact: 5W Public Relations.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10521947.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Version 2.0 of Award-Winning Proloquo2Go App for iPhone, iPad & iPod touch Speeds Up Communication, Adds New Voices and Customization Options
2. Kentucky Social Security Disability Benefits Lawyer with The Frank Jenkins Law Office Voices Support for Recent Expansion of Compassionate Allowance Program
3. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
4. Voices Against Brain Cancer Commends a Surgical Innovation That Lights Up Brain Tumors
5. Yakima Traumatic Injury Lawyer Mariano Morales Voices Support for Brain Injury Awareness Month
6. Voices Against Brain Cancer Comments on Link Between Cell Phone Use and Brain Cancer
7. Factoring Receivables & Factoring Invoices Experts Universal Funding Announces Move
8. Voices Against Brain Cancer Commends Andrew Bauer For Raising Awareness About Brain Cancer
9. Scientists identify major source of cells defense against oxidative stress
10. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
11. Will women use microbicides to protect themselves against HIV?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... ... Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – ... who don’t learn from history are doomed to repeat it.” , An analysis of CDRH’s ... But that takes time. , Take a close look at the warning letters the ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., ... have closed for the ISE Southeast Awards 2016. Finalists and winners of the ... ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 at the ...
(Date:2/12/2016)... ... 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance firm with ... will raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and ... is in a low-income area and has more than 60 2nd and 3rd graders ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement organization that ... partnership with San Ramon Regional Medical Center. Under the collaboration, the first of its ... to accommodate a more certain time frame for donor families for the recovery of ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  SI-BONE, Inc., a medical device company that pioneered ... minimally invasive surgical (MIS) device indicated for fusion for certain disorders ... (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , Minnesota ... York , Rhode Island , ...
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
Breaking Medicine Technology: